Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06825494 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Studies for the Treatment of Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started2025-04-08
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 18, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-12-10
Study Status, Study Design, Arms and Interventions, Contacts/Locations v2
Enrollment target134→194
Study sites29→32
Study arms4→5
InterventionsLM-108 injection 10mg/kg +penpulimab (Drug), LM-108 injection 600mg + penpulimab (Drug), LM-108 injection+Penpulimab+…→LM-108 injection 10mg/kg +penpulimab (Drug), LM-108 injection 600mg + penpulimab (Drug), LM-108 injection+Penpulimab+…
2025-04-17
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-03→confirmed 2025-04-08
2025-02-09
Original filing
This trial is part of a multicenter, open-label Phase Ib/II clinical study evaluating the efficacy, safety, and tolerability of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors. Phase Ib of Cohort A1 determines the dose of LM-108 in combination with penpulimab + oxaliplatin + capecitabine. Phase II explores the efficacy and safety of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors.
Trial Details
NCT Number NCT06825494
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 194 participants
Start Date 2025-04-08
Primary Completion 2026-03 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-18